Printed from Voxsanity (voxsanity.com.au) — NCT05353140 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Atrial Fibrillation
Atrial Fibrillation Trial, Recruiting
NCT05353140
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had a successful procedure to open blocked heart arteries (called PCI) due to chest pain caused by reduced blood flow (unstable angina or stable coronary artery disease)
- People who have a type of irregular heartbeat called atrial fibrillation that is not caused by a heart valve problem
- People who also have at least one of the following conditions: heart failure, high blood pressure, are aged 65 or older, have diabetes, or have previously had a stroke, a mini-stroke (TIA), or a blood clot
- People whose treating doctor has determined them to be eligible for long-term blood-thinning medication of a specific type (called a NOAC)
- People who are able to understand the study, provide written agreement to take part, and follow all study requirements
Who may not be able to join:
- People under 18 years of age
- People who are unable to give informed consent, or who are currently in another clinical trial that has not yet reached its main study goal
- Women who are pregnant or breastfeeding (a pregnancy test is required within 7 days before the procedure for women who could become pregnant)
- People with another serious illness where life expectancy is less than 3 years
- People whose heart and circulation are currently unstable
- People who have a known allergy or medical reason to avoid medications such as heparin, blood thinners, anti-clotting drugs, or contrast dye used in imaging
- People whose PCI procedure was performed due to a heart attack (STEMI or NSTEMI), or who had a heart attack as a complication of the PCI procedure
- People who have a medical reason that makes the left atrial appendage closure (LAAO) device unsuitable, or for whom the device is not considered necessary (confirm with trial site)
- People who have a condition other than atrial fibrillation that requires long-term blood thinning medication, such as having a mechanical heart valve
- People who have had, or are planning to have, any other heart or non-heart procedure or surgery within 30 days before or 60 days after the device implant (for example, cardioversion, ablation, or cataract surgery)
- People with active, ongoing bleeding
- People who have had a stroke or mini-stroke within the 30 days before enrolling in the study
- People with significant narrowing of the arteries in the neck (carotid artery disease) causing symptoms
- People with severely reduced kidney function (confirm specific measurement with trial site)
- People who have a blood clot in the left atrial appendage (a small pouch in the heart), as seen on imaging
- People with a specific type of hole in the heart (patent foramen ovale or atrial septal defect) that is considered high risk and needs treatment
- People whose heart anatomy is not suitable for the LAAO device
- People with rheumatic heart valve disease or significant narrowing of the mitral valve
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Ling Tao, M.D., Ph.D., Xijing Hospital
Phone: +86-18629551066
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
Xijing Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2022
Est. completion
20 September 2028
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Major adverse cardiac and cerebrovascular events (MACCE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.